Immobilization of human myeloperoxidase on silica gel for inhibitors assessment.

Jean-Michel Kauffmann, Pierre Van Antwerpen, Cédric Delporte, Karim Zouaoui Boudjeltia, Yalda Cobra Parsajoo

Journal: Journal of pharmaceutical and biomedical analysis 2025;264():116974

PMID: 40398244

Abstract

Myeloperoxidase (MPO), a hemo-protein present in neutrophils and monocytes, significantly contributes to immune responses against microbial pathogens. Increased MPO activity, however, promotes the production of highly reactive oxidized species in extracellular fluids that can damage host tissues causing inflammatory events. To explore the potential of MPO as a target for inhibitor screening, this study aimed to develop and evaluate a mini-reactor system based on immobilized MPO. Several immobilization strategies including physical adsorption and covalent binding, were tested using silica gel as the support material. Among them, immobilization via cyanogen bromide (CNBr) activation was selected as the optimal method based on long-term stability (> 90 % after 20 runs) and a relative activity of 60 % after immobilization. Kinetic parameters for HO were determined to characterize the enzymatic behavior post-immobilization, including K and V (46 ± 4 µM and 463 ± 38 µM/min, respectively). The system was then employed to evaluate the inhibitory potency (IC₅₀) of three model compounds-salicylhydroxamic acid (SHA), paroxetine (PARO), and 4-aminobenzohydrazide (4-ABAH)-on HOCl production in the presence of 10 µM H₂O₂. 4-ABAH emerged as the most potent irreversible inhibitor (IC₅₀ = 0.30 µM), while SHA was the least effective (IC₅₀ = 27.10 µM). Those results demonstrated that immobilized-MPO preserved its activity and exhibited good stability. This mini-reactor provides a reliable platform for inhibitor studies, offering potential applications in screening therapeutic compounds to mitigate MPO-related inflammatory conditions.

Copyright © 2025 Elsevier B.V. All rights reserved.

Address: RD3- Pharmacognosy, Bioanalysis and Drug Discovery, Faculty of Pharmacy, Universite Libre de Bruxelles, Boulevard du Triomphe, Campus Plaine CP 205/5, Brussels 1050, Belgium; Analytical Platform of the Faculty of Pharmacy, Universite Libre de Bruxelles, Boulevard du Triomphe, Campus Plaine CP 205/5, Brussels 1050, Belgium.; Laboratory of Experimental Medicine, Faculty of Medicine, Universite Libre de Bruxelles, Route de Gozee 706, Montigny-le-Tilleul 6110, Belgium.; RD3- Pharmacognosy, Bioanalysis and Drug Discovery, Faculty of Pharmacy, Universite Libre de Bruxelles, Boulevard du Triomphe, Campus Plaine CP 205/5, Brussels 1050, Belgium.; RD3- Pharmacognosy, Bioanalysis and Drug Discovery, Faculty of Pharmacy, Universite Libre de Bruxelles, Boulevard du Triomphe, Campus Plaine CP 205/5, Brussels 1050, Belgium; Analytical Platform of the Faculty of Pharmacy, Universite Libre de Bruxelles, Boulevard du Triomphe, Campus Plaine CP 205/5, Brussels 1050, Belgium. Electronic address: [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.